CSL Limited (CSL) - Research

$190.3700.14 (0.07%)
Prices as at 16:40, 23 Apr 2019

CSL Current Share Price+

Current Price $190.370
Open $190.000
High $190.850
Low $189.410
Last Close $190.510
Volume 876374
Price Movement $0.14 ( 0.07% )
  • +Security prices are delayed by at least 20 minutes and are indicative only.

CSL General Information

CSL Limited
CSL
http://www.csl.com.au
Biotechnology
86,256
453
CSL Limited
(CSL)
BUY
below
HOLD
up to
SELL
above
Current Price
$190.370 as at 16:40, 23 Apr 2019
Price at review
$190.370 on 14 Feb 19
Max Portfolio Weighting
Business Risk
Share Price Risk

CSL Related Research

CSL Company Overview

Business Description

CSL Limited (CSL) is a global biotechnology company that develops and delivers innovative medicines that save lives, protect public health and help people with life-threatening medical conditions live full lives. The operational businesses include CSL Behring and Seqirus provides life-saving products to more than 60 countries and employs 22,000 people. The Group operates predominantly in Australia, the USA, Germany, the United Kingdom and Switzerland.

CSL Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2020 F 2,994.58 661.93 11.40% 28.78 304.51 1.60% 0.0%
2019 F 2,687.55 594.07 20.20% 32.07 272.79 1.43% 0.0%
2018 A 2,236.22 494.36 26.90% 30.30 222.51 1.49% 0.0%

CSL Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2018 A 2019 F 2020 F 2018 A 2019 F 2020 F 2018 A 2019 F 2020 F
CSL (CSL) $87,462M 0.3775 0.1269 0.1290 36.7746 32.6345 28.9045 1.60% 1.40% 1.61%
Clinuvel Pharmaceuticals (CUV) $1,195M 0.8671 0.0000 0.0000 91.3858 0.0000 0.0000 0.08% 0.00% 0.00%
Mesoblast (MSB) $773M 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Monash IVF Group (MVF) $247M -0.2744 0.0000 0.0000 11.5766 0.0000 0.0000 5.71% 0.00% 0.00%
Polynovo (PNV) $602M 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%

CSL Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 1.10 33.00 15.60 2.58
Market 0.93 16.70 1.52 1.50
Sector 0.76 26.80 3.25 3.06

CSL Directors

Name Position Start Date
Mr Paul Perreault Chief Executive Officer, Managing Director 13 Feb 2013
Dr Robert Andrew Cuthbertson Non-Executive Director 17 Oct 2018
Ms Christine O'Reilly Non-Executive Director 16 Feb 2011
Mr Bruce Robert Brook Non-Executive Director 17 Aug 2011
Ms Marie Elizabeth McDonald Non-Executive Director 14 Aug 2013
Dr Megan Elizabeth Clark Non-Executive Director 16 Feb 2016
Dr Tadataka (Tachi) Yamada Non-Executive Director 1 Sep 2016
Mr Shah Abbas Hussain Non-Executive Director 13 Feb 2018
Dr Brian Anthony McNamee Non-Executive Director, Non-Executive Chairman 13 Feb 2018

CSL Management

Name Position
David Lamont Chief Financial Officer
Andrew Cuthbertson Chief Scientific Officer
John Marshall Levy Company Secretary
Fiona Mead Company Secretary,Head of Group Governance
William Campbell Executive Vice President & Chief Commercial Officer
Elizabeth Walker Executive Vice President & Chief Human Resources Officer
Greg Boss Executive Vice President Legal & Group General Counsel
Val Romberg Executive Vice President Manufacturing Operations & Planning
Karen Etchberger Executive Vice President Quality & Business Services
Gordon Naylor President, Seqirus

CSL Calendar of Events

Date Event
12 February 2020 Report (Interim)
13 September 2019 Report (Annual)
14 August 2019 Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.